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In recent years, circulating miRNAs have attracted interest as stable, non-invasive biomarkers for various pathological
conditions. Here, we investigated their potential to serve as minimally invasive, early detection markers for inflammatory
breast cancer (IBC) and non-inflammatory breast cancer (non-IBC) in serum. miRNA profiling was performed on serum
from 20 patients with non-IBC, 20 with IBC, and 20 normal control subjects. Real-time reverse transcription-polymerase
chain reaction (qRT-PCR) was applied to measure the level of 12 candidate miRNAs previously identified in other
research(miR-342-5p, miR-342--3p, miR-320, miR-30b, miR-29a, miR-24, miR-15a, miR-548d-5p, miR-486-3p, miR-451,
miR-337-5p, miR-335).We found that 4 miRNAs (miR-24, miR-342-3p, miR-337-5p and miR-451) were differentially
expressed in serum of IBC patients compared to non-IBC, and 3 miRNAs (miR-337-5p ,miR-451and miR-30b) were
differentially expressed in IBC and non-IBC patients combined compared to healthy controls. miR-24, miR-342-3p,
miR-337-5p and miR-451 were found to be significantly down-regulated in IBC patients compared to non-IBC. Likewise,
the expression level of mir-451 showed significant down-regulation in IBC serum, while mir-30b and miR-337-5p were
up-regulated in non-IBC serum comparatively to normal controls. Using receiver operational curve (ROC) analysis, we
show that dysregulated miRNAs can discriminate patients with IBC and non-IBC from healthy controls with sensitivity
ranging from 76 to 81% and specificity from 66 to 80%, for three separate miRNAs. In conclusion, our data suggest
that circulating miRNAs are potential biomarkers for classifying IBC and non-IBC, and may also be candidates for
early detection of breast cancer.
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Breast cancer (BC) is the most commonly diagnosed
cancer in women worldwide. In Tunisia, this tumor repre-
sents the leading cause of cancer death among women,
accounting for 30% of all malignancies in women and
with a particularly high proportion of inflammatory types
of breast cancer (Belkacémi et al. 2010).
Inflammatory breast cancer (IBC) is rare but the most
lethal form of locally advanced breast carcinoma, occur-
ring in 1% to 6% of all invasive breast tumors. (Lehman* Correspondence: r.marrakchi.triki@gmail.com
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in any medium, provided the original work is pet al. 2012); affected patients have a poor prognosis due
to infiltration of tumor emboli that metastasize within
the dermal lymphatic vessels of the skin overlying the
breast (Boussen et al. 2010). According to the American
Joint Committee on Cancer (AJCC), IBC is “a clinico-
pathologic entity characterized by diffuse erythema and
edema (i.e., peau d’orange) of the breast, often without
an underlying palpable mass” (Lehman et al. 2012). Fur-
thermore, the AJCC’s staging scheme defines IBC as T4d
tumor at diagnosis, and characterizes it as typically af-
fecting young women, often during their childbearing
years (Laere et al. 2005). At diagnosis, a majority of pa-
tients have axillary lymph nodes involved, and one third
present with distant metastases (Bertucci et al. 2005).n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Table 1 Clinicopathological features of inflammatory





N = 20 (% ) N = 20 (%) N = 20 (%)
Age range 34-70 29-78 21-80
Mean age 49.0 50.2 45.5
Menopausal status
Pre-menopausal 10 50% 10 50% 10 50%
Post-menopausal 10 50% 10 50% 10 50%
Histological grade
I 0 0% 0 0%
II 9 45% 7 35%
III 11 55% 13 65%
Node status
N0 2 10% 7 35%
N1 16 0% 13 65%
N2 2 10% 0 0%
N3 0 80% 0 0%
Tumor
T1 0 0% 0 0%
T2 0 0% 6 30%
T3 0 0% 13 65%
T4 20 100% 1 5%
Metastasis
M0 14 70% 4 20%
M1 0 0% 2 10%
Unknown 6 30% 14 70%
ER status
Positive 3 15% 11 55%
Negative 17 85% 9 45%
PR status
Positive 4 20% 11 55%
Negative 16 80% 9 45%
HER2 status
Positive 13 65% 13 65%
Negative 7 35% 7 35%
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signatures containing information which may enable ex-
planation of the mechanisms of tumor development and
progression and the poor prognosis observed in IBC. In-
deed, several studies comparing IBC to non-IBC have
demonstrated a specific mRNA expression signature in
IBC that is significantly enriched for genes involved in
cell motility, inflammation, immune response and stem
cell biology (Bertucci et al. 2004; Ben Hamida et al.
2008). Furthermore, expression profiling performed by
Marrahchi et al. have further strengthened the evidence
of the role of WISP3 as a tumor suppressor gene and
RhoC as an oncogene which act in concert to give rise
to the highly aggressive IBC phenotype in the Tunisian
population. (Marrakchi et al. 2009).
Some studies have noted the dysregulation of several
miRNA in IBC tumors, but (Iorio et al. 2005; Blenkiron
et al. 2007; Auwera et al. 2010), no study has focused on
miRNA levels in sera of patients with IBC. The aim of
this study was to identify a molecular signature of IBC
based on miRNA profile in serum and to use this profile
as an early diagnosis criterion. To this end, we present
the first investigation of a panel of miRNA in the serum
of inflammatory breast cancer patients and compared




Written informed consent was obtained from all partici-
pants involved in this study. This study was approved by
the Georgetown University Institutional Review Board
and the Ethical Committee of Pasteur Institute of Tunis,
Tunisia.
Serum samples and clinical data
In this study, a total of 20 women with non-IBC, 20
women with IBC, and 20 cancer-free women were re-
cruited. Peripheral blood samples (5 ml per subject)
were obtained from each study subject and were collected
between March 2011 and January 2012 from patients be-
ing diagnosed and treated at Hannibal International Clinic
of Tunis at the time of diagnosis before they underwent
any therapeutic procedure. Control blood samples were
collected at the same period from healthy women volun-
teers with no history of malignant diseases, no blood do-
nations received in the previous 3 years, and no current
inflammatory conditions; they were matched to the cases
on menopause status. The blood tube was centrifuged at
1200 × g for 10 min at 4°C followed by careful separ-
ation of serum. Another centrifugation was performed
for 10 min at 10,000 × g at 4°C to remove the cellular
debits. The serum was stored at −80°C until it was used
for RNA extraction.The clinico-pathological data and tumor characteris-
tics of the patients at time of diagnosis are illustrated in
Table 1. We classified the cancer stage according to the
TNM staging system of the seventh edition of the AJCC
Cancer Staging Manual. There were no statistical differ-
ences in age, estrogen receptor, progesterone receptor,
and Her2/neu between the two patients groups. Patient
histopathology results were confirmed by the patholo-
gist’s examination of the surgical resection.
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Total RNA was extracted from 500 μl serum using mir-
Vana ™PARIS™Kit from Life Technologies according to
manufacturer’s protocol. Briefly, 500 μl of 2× Denaturing
Solution was added to each sample. Total RNA was ex-
tracted with acidic phenol:chloroform. The aqueous
phase was loaded onto the Filter Cartridge after the
addition of 1.25 volume of 100% ethanol. After several
washing processes, the RNA was eluted into 60 μl of
RNase-free water. The RNA concentration and purity
were controlled by UV spectrophotometry using a Nano-
drop ND-1000 a verifier (Thermo Scientific). The RNA
specimens were stored at − 80°C until reverse transcrip-
tion.The corresponding cDNAs were made using TaqMan
MicroRNA reverse transcription (RT) reagents and spe-
cific primers for the miRNAs (Applied Biosystems). The
amount of RNAs used for RT was 2 ng and the cDNA
specimens were stored at − 20°C until PCR.miRNA quantification by real-time quantitative PCR
Real-time PCR was performed for each of 13 miRNAs
identified in previous research, as described above
(hsa-miR-5p, hsa-miR-3p, hsa-miR-320, hsa-miR-30b,
hsa-miR-29a, hsa-miR-24, hsa-miR-15a, hsa-miR-548d-
5p, hsa-miR-520a, hsa-miR-486-3p, hsa-miR-451, hsa-
miR-337-5p, hsa-miR-335). For the 20 μl reaction,
1.33 μl cDNA was combined with 10 μl of TaqMan®
Universal PCR Master Mix II (2×), without uracil-N-
glycosylase, 1 μl of the TaqMan miRNA assay, and
7.67 μl of nuclease-free water. The reaction mixtures
were incubated at 95°C for 10 min, followed by 40 cycles
of 95°C for 15 s and 60°C for 1 min.All assays were per-
formed on the Applied Biosystems 7900 HT Sequence
Detection System following the manufacturer’s protocol.
For each sample, the miRNA expression levels were
assayed in triplicate and were run with endogenous con-
trol RNU-48 (small nuclear RNA) also in triplicate, with
a single no template negative control reaction (seven re-
actions total per sample per miRNA), and were calculated
using the 2− ΔΔCtmethod (Livak & Schmittgen 2001). The
cycle threshold (Ct) values were calculated as the number
of cycles needed for the fluorescence to reach a specific
threshold level of detection.Statistical methods
The miRNA data were analyzed using the programming
language R based on the methodology described by
Livak et al. For each miRNA, we calculated the average
cycle threshold difference (ΔCt) across multiple samples
within a groupthe fold change between two groups, and
the statistical significance of the observed difference be-
tween two groups (p-value). Statistical significance of
the change in expression between the two groups (BCvs. IBC) is determined by using the two-sample t-test as-
suming unequal variance.
Receiver operating characteristic (ROC) curves and the
area under the ROC curve (AUC) were used to evaluate
the diagnostic effects of the miRNAs and to determine ap-
propriate cut-off points.
The sensitivity and specificity of the optimum cut-off
point were defined as those values that maximized the
area under the ROC curve. All statistical analyses were
performed using SPSS 15.0 software, and p value < 0.05
was considered statistically significant.Results
miRNA expression profile of IBC, non-IBC, and healthy
controls
Among the 12 miRNAs analyzed, 5 miRNAs were differ-
entially expressed in the serum of the 3 groups of subjects
(Table 2), using the criteria of at least two-fold differential
expression and significance level of < 0.05. Regarding
the comparison of IBC patient samples to healthy con-
trols we found that only miR-451 was significantly dysreg-
ulated (p = 0.019), showing significant down-regulation
(15.8-fold) in IBC sera comparison to healthy controls. In
comparing non-IBC sera with normal sera we observed
that mir-337-5p and mir-30bwereover expressed in non-
IBC (p = 0.049; 16.8-fold increase, and p = 0.032; 14.4 folds
increase, respectively). In terms of expression levels of
miRNAs in IBC sera compared to non-IBC sera, we found
that miR-24, miR-342-3p, miR-337-5p and miR-451 were
differentially expressed among these, mir-451 was signifi-
cantly down-regulated (57.5-fold reduction) in IBC serum
compared non-IBC serum (p = 0.000), while, miR-337-5p
was up-regulated in non-IBC serum compared to IBC
serum (p = 0.025, 12.3-fold difference). Likewise, mir-342-
3p and mir-24 levels were higher in non-IBC (10.5-fold;
p = 0.047, and 16-fold, p = 0.016, respectively.Profiles of individuals based on the expression level of 12
miRNAs studied
The clustering of miRNA expression profiles from the
three groups of subjects is shown in Figure 1. In each
group; the levels of the miRNAs are positively corre-
lated. In contrast the results of the heat map that was
constructed for the 12 measured miRNAs demonstrated
a diversity of expression profiles, with 9 different profiles
for healthy controls, 17 for IBC patient sera, and 12 for
non-IBC. A downward trend of miRNAs is observed in
the IBC subjects; while in non-IBC sera a tendency to
over expression was observed. However, no clear clusters
corresponding to the three groups were evident. In the
control group, where most of the profiles were associated
with low miRNA expression, two profiles with high ex-
pression were also observed and are shown in Figure 1.
Table 2 Differentially expressed miRNAs obtained from comparison of subjects with IBC or non-IBC compared to healthy controls
miRNAs IBC serum
Mean ± SD log2
(fold change value)
Non-IBC serum
Mean ± SD log2
(fold change value)
P value Healthy serum
Mean ± SD log2
(fold change value)
IBC serum
Mean ± SD log2
(fold change value)
P value Healthy serum
Mean ± SD log2
(fold change value)
Non-IBC serum
Mean ± SD log2
(fold change value)
P value
has-mir-24 -7.4 -3.4 0.016 -6.1 -7.4 NS -6.1 -3.4 NS
has-mir-342-3p -5.9 -2.6 0.047 -5.5 -5.9 NS -5.5 -2.6 NS
has-mir-451 -11.8 -5.9 0.000 -7.8 -11.8 0.019 -7.8 -5.9 NS
has-mir-30b -4.8 -2.7 NS -6.7 -4.8 NS -6.7 -2.7 0.049
has-mir-337-5p -3.1 0.5 0.025 -3.4 -3.1 NS -3.4 0.5 0.032
has-mir335 -4.9 -2.5 NS -4.9 -4.9 NS -4.9 -2.5 NS
has-mir-320 −9.6 -6.3 NS -7.2 -9.6 NS -7.2 -6.3 NS
has-mir-548-5d -0.6 0.0 NS -2.3 -0.6 NS -2.3 0.0 NS
has-mir486-3p -3.4 -1.7 NS -4.0 -3.4 NS -4.0 -1.7 NS
has-mir-342-5p -2.6 -0.8 NS -4.0 -2.6 NS -4.0 -0.8 NS
has-mir-15a -4.2 -2.6 NS -4.3 -4.2 NS -4.3 -2.6 NS















Figure 1 Hierarchical clustering of miRNAs expression. miRNAs profiles of 17 IBC, 12 non-IBC and 9 healthy controls were clustered based
on the 3 groups (IBC, non-IBC and healthy controls). Samples are in columns, miRNAs in rows. High expression values are indicated by bright red
shades, low expression values are shown in green.
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as potential prognosis markers
To evaluate whether these serum miRNAs can be used as
potential diagnostic markers for IBC or non-IBC, receiver-
operating characteristic (ROC) curve analyses were
performed.mir-30b yielded an AUC of 0.748 with 76% sen-
sitivity and 66% specificity in discriminating non-IBC from
a cut-off value of −16.8 (Figure 2a), while mir-337-5p
yielded AUC of 0.816 with 81% sensitivity and 66% specifi-
city in differentiating non-IBC from normal controls, from
a cut-off value of −14.4 (Figure 2c). Likewise, mir-451
yielded an AUC of 0.783 with 81% sensitivity and 80.0%
specificity in discriminating the IBC subtype from a cut-
off value of −57.5 (Figure 2b).Discussion
Tumor tissue miRNAs have been demonstrated to be
associated with the pathogenesis of breast cancer and pro-
posed to be used as biomarkers for diagnosis and progno-
sis (Lowery et al. 2008); (Iorio et al. 2005); (Blenkiron et al.
2007). (Giglio et al. 2013). At least 24 candidate oncogenes
with gains at the DNA level, discovered with comparative
genomic hybridization (CGH) studies, have been reported
for IBC in contrast to non-IBC breast tumors. Gene ex-
pression studies also support genetic heterogeneity for IBC
(Bekhouche et al. 2011).
Although notable progress has been made in the last dec-
ade in the study of IBC, early detection is one of the major




























Figure 2 Evaluation of mir-30b, mir-451 and mir-337-5p expression in IBC and non-IBC serum by receiver operating characteristics
(ROC) curve analysis. Fig 2(a): Evaluation of mir-30b expression in non-IBC serum by curve ROC. Fig 2(b): Evaluation of mir-451 expression in
IBC serum by curve ROC. Fig 2(c): Evaluation of mir-337-5p expression in non-IBC serum by ROC curve.
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stranded small RNAs, offer a promising new avenue of re-
search since they are responsible for regulating gene ex-
pression on the post-transcriptional level. They accomplish
this regulation through binding, due to partial or total se-
quence homology to target mRNAs, thus inhibiting the
translation of protein from these mRNAs or by promoting
their degradation (Wu et al. 2009). Through this process,
miRNAs are involved in the regulation differentiation, me-
tabolism, proliferation and apoptosis (Chen et al. 2012). It
has been observed that dysregulated miRNA expression re-
sulted in a wide array of pathological events, including can-
cer, indicating that miRNAs may become valuable
molecular markers for detection and prognosis of tumors.
Compared to protein-based biomarkers, miRNA offers sev-
eral advantages: the complexity of miRNA is much lower
than that of proteins; the sequences of many miRNAs are
conserved across species; the expression of some miRNAs
are restricted to specific tissues or biological stages ; and the
levels of miRNAs can also be easily measured by various
commonly used laboratory methods (Friedman et al. 2012).
More recently, Mitchell et al., reported that miRNAs
existed in serum/plasma, and were originated from can-
cer tissue (Mitchell et al. 2008). The extreme stability of
circulating miRNAs appeared due to their resistance to
RNase digestion and to their protection from degrad-
ation through inclusion in various protein complexes or
membranous particles such as exosomes or microvesi-
cles. The miRNAs are particularly resistant to harsh con-
ditions such as extended storage and multiple freeze-
thaw cycles which holds great promise for the use of
miRNAs as distinctive, non-invasive cancer biomarkers
(Ng et al. 2013);(Blondal et al. 2012).
Since the discovery of circulating miRNAs, numerous
studies on miRNA and cancer have been published
(Volinia et al. 2006). Focusing on breast cancer, a pilot
study performed by Roth C et al. provided the first evi-
dence that tumor-associated circulating microRNAs are
elevated in the blood of breast cancer patients and asso-
ciated with tumor progression (Roth et al. 2010).
Moreover, Heneghan et al. found that expression of miR-
195 was significantly elevated in breast cancer patients
compared to healthy controls (Heneghan et al. 2010).
The role of serum miRNA in breast cancer has not been
thoroughly studied. Our work is based on the hypothesis
that circulating miRNAs in serum can potentially serve as
novel, minimally invasive biomarkers for early detection of
inflammatory and non-inflammatory breast cancer. In the
present study, we investigated the potential of 12 circulating
miRNAs, selected from previous studies, by analyzing serum
profiles of IBC, non-IBC and matched healthy controls. The
clustering of miRNA expression profiles that we observed
identified four groups of miRNAs that sufficiently discrimi-
nated the three groups of patient sera in a blinded fashion.Moreover, normal sera profiles are rather related to
low levels of miRNAs which is in agreement with the
fact that most of the miRNAs studied could be consid-
ered oncogenes (Du et al. 2013) (Li et al. 2010). However
two profiles with high miRNA expression and close to
some non-IBC patient sera, are observed in controls lead-
ing to a doubt on their normality. In other words such
profiles could be associated to the first steps of the disease.
Since no clear clusters corresponding to the three serum
groups have been carried out, this hypothesis needs more
investigation to be confirmed.
Moreover, our results have shown that taken individually
some serological mRNA could be pertinent markers of
breast cancer. Indeed, we observed that, from the 12 miR-
NAs studied, five miRNAs (mir-24, mir-342-3p, mir-30b,
mir-337-5p and mir-451) were significantly dysregulated
in the serum of the 3 groups studied, among which four
discriminated between IBC and non-IBC patient sera.
Although serum samples are easily acquired in a rela-
tively noninvasive manner, and isolated miRNAs are read-
ily detected by qRT-PCR, a widely used clinical and
laboratory technique, it should be mentioned that miRNA
profiles in serum are not necessarily representative of their
expression in the tumor. Hence, our results revealing only
four discriminative miRNAs between IBC and non-IBC
sera are discordant with a previous study on breast tumors
that observed 3 times as many discriminative miRNAs. In-
deed, since miRNA presence is often observed in healthy
subject sera, it is obvious that it may be a consequence of
normal physiology. In breast cancer patient serum, this
serological expression may be viewed as a cause or a con-
sequence of the oncogenic process. Therefore, if it can be
shown prospectively that the levels are over- or under-
expressed prior to cancer diagnosis, the determination of
the serum miRNA profiles in breast cancer patients may
be quite meaningful. In our study, mir-342-3p and mir-
24were significantly up-regulated in non-IBC as compared
with IBC. This result is in agreement with a previous re-
port on IBC and non-IBC miRNAs expression in tumors,
while our results differed in showing a significant up-
regulation of miR-337-5p in IBC (Iorio et al. 2005). This
up-regulation phenomenon may also be the case for miR-
30; moreover the miR-30 family is able to suppress apop-
tosis (Li et al. 2011) and is up-regulated in non-IBC
tumors in comparison with IBC (Iorio et al. 2005)/
(Blenkiron et al. 2007). Finally, we also observed that
mir-451 was significantly down-regulated in IBC serum as
compared with non-IBC and with healthy controls, with
adequate specificity and sensibility to serve as a marker
for IBC. The lower expression level of mir-451 observed
in serum of IBC comparatively to normal sera could be
either the consequence of the tumor development or
the cause of the disease through more general mecha-
nisms leading to the oncogenic process in IBC. In the
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early diagnosis marker of IBC. Our results are in agree-
ment with previous studies showing mir-451 as a tumor
suppressor (Li et al. 2013).
In conclusion, if validated in future, larger studies,
mir-451 could be considered as a serological marker for
IBC, and mir-337-5p and mir-30 for non-IBC, with clear
utility in early diagnosis and/or disease prognosis studies.
Therefore the continued study of these miRNA dysregu-
lation pathways may lead to breast cancer prevention
strategies.
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